|
Jul 21
|
Why Alkermes Tumbled On Its Positive Narcolepsy Study
|
|
Jul 21
|
Takeda Pharmaceutical Receives FDA 510(k) Clearance for Hyqvia Devices
|
|
Jul 21
|
Takeda Receives FDA 510(k) Clearance for HyHubTM and HyHubTM Duo Devices to Simplify HYQVIA® Administration
|
|
Jul 17
|
Keros Therapeutics Announces the First Patient Dosing in the Phase 3 RENEW Clinical Trial of Elritercept
|
|
Jun 30
|
Takeda Announces U.S. FDA Approval of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1
|
|
Jun 27
|
Tempus AI's Data Business Keeps Scaling Up: Can the Growth Pace Last?
|
|
Jun 27
|
Will Strong Asceniv Sales Drive ADMA Biologics Further?
|
|
Jun 25
|
Liver Organoid Breakthrough: Generating Organ-Specific Blood Vessels
|
|
Jun 25
|
Ocular Therapeutix (OCUL) Moves 8.6% Higher: Will This Strength Last?
|
|
Jun 25
|
ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today?
|
|
Jun 25
|
Takeda Announces New Assignments of Directors
|
|
Jun 24
|
Protagonist Therapeutics, Takeda Pharmaceutical Announce Positive Phase 3 Rusfertide Results for Polycythemia Vera
|
|
May 14
|
The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 1
|
|
Feb 15
|
Is Takeda Pharmaceutical Company Limited (TAK) the Best Japanese Stock to Buy in 2025?
|
|
Feb 14
|
Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?
|
|
Feb 12
|
BBI announces $31m facility for Shire to enhance asset finance
|
|
Jan 2
|
Japanese Stocks Are in the Spotlight Again. Hopes Are High for 2025.
|
|
Oct 9
|
WAVE Life Sciences Ltd (WVE) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Rising ...
|
|
Jun 24
|
FDA Expands argenx's (ARGX) Vyvgart Label to Treat Rare Disorder
|
|
Jun 24
|
Takeda reports positive data from Phase IIb trial of ITP treatment
|